Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 68 Matches

Cycloguanil

Model Files Publication

Brand Name(s) include: N/A

Disease: Malaria

Drug Class: Antimalarials

Date Updated: March 2022

Related drugs: Proguanil

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	Formed by CYP2C19, CYP3A4; unknown clearance mechanism
Perpetrator DDI	CYP2D6 Inhibitor
Validation	Proguanil and cycloguanil files were built using in vitro and clinical (Jeppersen et al., 1997) data 5 clinical studies describing single and multiple dose exposure of cycloguanil were used to verify the PBPK model. 60% of studies were within 2-fold, of which 40% were within 1.5-fold. A clinical DDI study where proguanil was the victim of a CYP2C19-mediated DDI was accurately recovered using the PBPK model.
Limitations	Prediction of cycloguanil exposure was complicated by not knowing the polymorphism classification of subjects in each study, hence the model performance was deemed acceptable using the criteria of being within 2-fold of observed. Verification needed for perpetrator DDI assessment as literature data is unavailable at this time
Updates in V19	Recalculated fm values using the corrected dose administered in Jeppesen et al., 1997 Previous version used paper calculation of total clearance which did not account for the weight of the salt in the 200 mg dose administered Model converted from minimal to full PBPK distribution model Updated in vitro data Updated CYP2D6 IC₅₀

Search Score: 1

Cefuroxime_V12R1_FDA_20150709

Model Files Publication

Table 1 of main paper and further discussion in supplemental file. IV only. Key feature is the use of mechanistic kidney model to simulate the effect of severe renal impairment and probenecid inhibition.

Search Score: 1

Chlorzoxazone_RES_V20R1_Simcyp_20210512

Model Files Publication

The RES-Chlorzoxazone file was primarily developed as an inhibitor of CYP3A4. This document provides: 1. Examples of model performance 2. A summary of the key pharmacokinetic features of Chlorzoxazone considered within the model.

Search Score: 1

Amodiaquine

Model Files Publication

Brand Name(s) include: Basoquin, Camoquin, Flavoquin, Coarsucam

Disease: Malaria

Drug Class: Antimalarials

Date Updated: June 2021

The model at-a-glance

Absorption Model	First-Order
Volume of Distribution	Full PBPK (Method 2)
Route of Elimination	CYP2C8 = 72%; Additional HLM = 28%
Perpetrator DDI	CYP2D6
Validation	Four clinical studies describing single and multiple dose exposure of amodiaquine were used to verify the PBPK model. In comparison of predicted vs. observed AUC, 75% of the studies were 2-fold and 50% were within 1.5-fold. A clinical DDI study where amodiaquine was the victim of a CYP2C8-mediated DDI was accurately recovered using the PBPK model.
Limitations	Clinical data has not been used to verify amodiaquine as a perpetrator of CYP2D6-mediated DDIs
Updates in V19	Updated in vitrodata fu: 0.033 -> 0.089 B:P: 1.3 -> 1.1 DEAQ Ki for CYP2D6 (µM) – 1.7 -> 1.6 Converted from minimal PBPK model to full PBPK model Recalculated retrograde clearance for CYP2C8 CL_int and additional HLM CL_int

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Cycloguanil

The model at-a-glance

Cefuroxime_V12R1_FDA_20150709

Chlorzoxazone_RES_V20R1_Simcyp_20210512

Amodiaquine

The model at-a-glance

Your Privacy